Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Chromatin Bioscience's synthetic promoter enables EsoBiotec's ESO-T01 CAR-T therapy to progress to clinical trials

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antige. (BCMA) CAR-T...

Next Generation Gene Therapeutics (NGGT) announces the publication of early clinical trial results for NGGT001, a treatment for Bietti's Crystalline Dystrophy (BCD)

NGGT Inc., a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced the publication in the journal JAMA Ophthalmology of the results from a dose-escalation study in...

Matthew Fyfe has been appointed as Chief Scientific Officer as Outrun Therapeutics expands its leadership team

Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, announces the appointment of Matthew Fyfe as its Chief Scientific Officer. Matthew has over 25 years' experience in drug discovery and development across...

NTx announces the full commercial availability of NTxscribe to broadly enable RNA therapies

Nature’s Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, announced the full commercial availability of NTxscribe®, a benchtop, continuous flow RNA in vitro transcription (IVT) and...

Dr. Alastair Leighton, a biopharma veteran, has been hired as Chief Operating Officer by Chemify

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three...

Ouro Medicines launches to transform treatment for immune-mediated diseases with innovative therapies

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in...

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a...

Long Island University alumnus Dr. Howard Murad '62 launches the Inclusive Wellness Initiative with the Arnold & Marie Schwartz College of Pharmacy and Health Sciences

Dr. Howard Murad, a 1962 graduate of Long Island University's Arnold & Marie Schwartz College of Pharmacy and Health Sciences and an internationally recognized innovator in the science of skin care, is establishing the Dr. Howard Murad '62...

RiDYMO® develops a cyclic peptide targeting the "undruggable" β-catenin in just two months

In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months. This innovative AI-driven approach combines advanced...

NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. "Kadimastem", a clinical-stage cell...

Cardurion Pharmaceuticals has named Charlotte Newman as Chief Business Officer

Cardurion Pharmaceuticals, Inc. a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as...

PBS Biotech Secures $17M and Expands Leadership to Accelerate Next-Gen Cell Therapies

PBS Biotech ("PBS"), a provider of innovative single-use bioreactor systems and bioprocess development services, has secured $17 million in follow-on growth capital from Avego Management, LLC ("Avego") and BroadOak Capital Partners ("BroadOak")....

Axio BioPharma Partners with eMBR Genomics to Manufacture and Distribute Proprietary MKLP1 Pro™ Antibodies

In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro™ antibodies, KIF23 gene – the same tools used by the world's leading Midbody Remnants (MBRs) researchers. This strategic...

Strategic Expansion Expands Fusion Orthopedics' Foot & Ankle Reach

Fusion Orthopedics USA, LLC announced that it has expanded its robust product portfolio with the addition of the Metalogix External Fixation Systems. A seamless transition of Metalogix’s operations, distribution, and hospital accounts to Fusion is...

Spyre Therapeutics Announces Inducement Award Grants

Spyre Therapeutics, Inc. a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of...

Genesis Medtech secures Chinese approval for its groundbreaking 90° articulation powered surgical stapler, setting new standards in precision surgery

Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for market release in China by the National Medical Products Administration (NMPA). Independently...

Eden has launched the world’s first compounded GLP-1 prescription gummy, offering a novel and convenient approach to weight management treatment

Eden has launched the world's first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format, this innovative format reimagines how individuals approach GLP-1 programs in the United...

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers. Epinephrine Injection, USP is a...

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

Isotopia is proud to announce a groundbreaking partnership with LIVEKIDNEY.BIO, a clinical-stage biotech innovator, to support the development of a critical component for its revolutionary lupus nephritis therapy. This collaboration offers the...

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy...